Acute hemodynamic changes during far infrared treatment of the arteriovenous fistula in hemodialysis patients

September 1, 2023

Abstract

Background: The arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis (HD) treatment and

preservation of a stable vascular access is crucial. Long term Far Infrared Radiation (FIR) has been found to increase

access flow together with an enhanced maturation and patency of the AVF. The acute effects of FIR on access flow have

been sparsely described and the results are contradictory, perhaps due to differences in measurement conditions and

other factors of importance for access flow.

Methods: Twenty patients in HD with an AVF were included. Each patient was randomized to receive either FIR

(FIR group) or no FIR (control group). The acute changes in access flow were investigated in both groups on the

second dialysis day of the week and during the first 1.5 h of the dialysis session. Concomitant changes in hemodynamic

parameters of importance for access flow were also explored.

Results: There was no significant change in access flow in the FIR group compared with the control group (median

(Interquartile Range)) (−10 (−413.8; 21.3) ml/min vs −17.5 (−83.8; 76.3) ml/min, p = 0.58). There was no significant

difference in any of the hemodynamic parameters between the FIR and the control group; cardiac output (−0.7 (−1.2;

−0.2) l/min vs −0.4 (−0.9; 0.1) l/min, p = 0.58), cardiac index (−0.3 (−0.5; −0.1)) l/min/m2 vs −0.3 (−0.4; 0) l/min/m2, p = 0.68),

mean arterial pressure (5.5 (−1.8; 8.4) mmHg vs 1.5 (−3; 6.3) mmHg, p = 0.35) and total peripheral resistance (2 (1.8; 3.4)

mmHg × min/l vs 1 (−0.3; 3.1) mmHg × min/l, p = 0.12).

Conclusion: In this trial, with a highly standardized set-up, one session of FIR did not result in any acute changes in

access flow. This was not due to differences in the hemodynamic parameters between the groups.

-J Vasc Access. 2023 Jul;24(4):739-746.

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
February 12, 2026
On 9–10 February 2026, FIRAPY joined Unex Corporation (Japan) at World Health Expo – WHX Dubai 2026, held at the Dubai Exhibition Centre, Expo City Dubai. This was FIRAPY’s first time participating in WHX Dubai, marking an important step in expanding our presence in the Middle East and surrounding regions.  WHX Dubai (World Health Expo) is one of the region’s most important healthcare exhibitions, bringing together thousands of healthcare professionals, industry leaders, and innovators from more than 100 countries. The event combines a large-scale trade show with conferences and forums that highlight new technologies, clinical best practices, and emerging models of care.
December 29, 2025
Authors: Hamed Ali Ahmad Alshahri, Omaima Farah Al Jabal Published in: World Advances in Renal Medicine Vol.1, No.3 (2025) Read the full article
42th Chilean Society of Nephrology
December 3, 2025
FIRAPY made its debut at the Chilean Society of Nephrology Congress, presented by Mirusta and featured in a fistula care workshop, sparking local clinical interest.
More Posts